Although imatinib mesylate (Novartis, Switzerland) is currently the most effective drug with low toxicity available for treating patients with chronic myeloid leukemia (CML), approximately 10–15 ...

Leukemia - Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. ... Switzerland, is highly appreciated.

Background and Objective: Imatinib mesylate is the first effective therapy for advanced unresectable gastrointestinal stromal tumours (GIST). Adoption of this therapy in clinical practice is ...

Patients with GBM at any recurrence received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule. The imatinib mesylate dose was 500 mg twice a day for ...

Results of TETimaX Trial of Langerhans Cell Histiocytosis Treatment and Perspectives on the Role of Imatinib Mesylate in the Era of MAPK Signaling, Biomedicines, 9, 12, (1759), (2021). https://doi ...

In a recent cross-sectional study, Berman et al. found that some patients who were treated with imatinib mesylate had hypophosphatemia, with low-normal serum calcium levels, elevated levels of ...

The selective BCR-ABL1 kinase inhibitor imatinib mesylate (Gleevec) has been found to be safe and effective following almost 11 years of follow-up in patients with chronic myeloid leukemia.

Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study . JCO 23 , 585-590 (2005). DOI: ...

Imatinib mesylate, also known as Gleevec, is showing early signs of promise in preclinical trials against Ewing's sarcoma, a bone tumor in children and adolescents. In a study in the November 20 ...

(RTTNews) - Inhibikase Therapeutics, Inc. (IKT) announced the completion of its bioequivalence study of IkT-001Pro compared to 400 mg imatinib mesylate. The company said its study met expectations ...